Healthy Living South Dakota: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthy Living South Dakota.

September 2025

Mo	Tu	We	Th	Fr	Sa	Su
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30

October 2025

Mo	Tu	We	Th	Fr	Sa	Su
		1	2	3	4	5
6	7	8	9	10	11	12
13	14	15	16	17	18	19
20	21	22	23	24	25	26
27	28	29	30	31

November 2025

Mo	Tu	We	Th	Fr	Sa	Su
					1	2
3	4	5	6	7	8	9
10	11	12	13	14	15	16
17	18	19	20	21	22	23
24	25	26	27	28	29	30

Press releases published on November 7, 2025

November 7, 2025

Celldex to Present at Upcoming Investor Conferences

GlobeNewswire

November 7, 2025

Immunocore presents Phase 1 data for hepatitis B candidate at AASLD’s The Liver Meeting

GlobeNewswire

November 7, 2025

Press Release: ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA priority review

GlobeNewswire

November 7, 2025

Communiqué de presse : ACAAI : L’étude pivot Dupixent menée par Sanofi et Regeneron a atteint l’ensemble de ses critères d’évaluation principaux et secondaires, réduisant les signes et symptômes de la rhinosinusite fongique allergique...

GlobeNewswire

November 7, 2025

Dr. Adrian Bot joins Immuthera to support the company with his unique experience in commercialization of groundbreaking cell therapies

GlobeNewswire

November 7, 2025

Vor Bio to Participate in Upcoming Investor Conferences

GlobeNewswire

November 7, 2025

Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences

GlobeNewswire

November 7, 2025

Assembly Biosciences Presents Positive Phase 1b Data for Next-Generation Capsid Assembly Modulator ABI-4334 at AASLD The Liver Meeting®

GlobeNewswire

November 7, 2025

Atea Pharmaceuticals Presents New Data Supporting the Fixed-Dose Combination of Bemnifosbuvir and Ruzasvir as a Potential Best-in-Class Regimen for Treatment of Hepatitis C Virus Infection at The Liver Meeting® 2025

GlobeNewswire

November 7, 2025

Rivus Pharmaceuticals Announces New Data from Phase 2 M-ACCEL Trial of HU6 in MASH in Late-Breaker Oral Presentation at AASLD The Liver Meeting® 2025

GlobeNewswire

November 7, 2025

Pelthos Therapeutics Acquires Xepi® (ozenoxacin) Cream, 1% and Announces $18 Million Private Convertible Notes Financing

GlobeNewswire

November 7, 2025

Vaxart to Host Upcoming Conference Calls

GlobeNewswire

November 7, 2025

Biofrontera Inc. announces sale of license to Xepi® Antibiotic Cream to Pelthos Therapeutics Inc. for up to $10M

GlobeNewswire

November 7, 2025

ORYZON Reports Financial Results and Corporate Update for Quarter Ended September 30, 2025

GlobeNewswire

November 7, 2025

Dupixent® (dupilumab) Pivotal Trial Met All Primary and Secondary Endpoints, Reducing Signs and Symptoms of Allergic Fungal Rhinosinusitis (AFRS); sBLA Accepted for FDA Priority Review

GlobeNewswire

November 7, 2025

Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025

GlobeNewswire

November 7, 2025

Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

November 7, 2025

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025

GlobeNewswire

November 7, 2025

Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting

GlobeNewswire

November 7, 2025

Abeona Therapeutics® Announces Date of Third Quarter Financial Results and Upcoming Investor Conference Participation

GlobeNewswire